Cocrystal Prediction of Bexarotene by Graph Convolution Network and Bioavailability Improvement
Bexarotene (BEX) was approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL). The poor aqueous solubility causes the low bioavailability of the drug and thereby limits the clinical application. In this study, we developed a GCN-based deep learning model (CocrystalGCN) for i...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
MDPI AG
2022-10-01
|
| Sraith: | Pharmaceutics |
| Ábhair: | |
| Rochtain ar líne: | https://www.mdpi.com/1999-4923/14/10/2198 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|